0.00Open0.74Pre Close0 Volume384 Open Interest282.50Strike Price0.00Turnover781.74%IV-4.19%PremiumMay 2, 2025Expiry Date12.06Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7806Delta0.1483Gamma365.46Leverage Ratio-989.1791Theta0.0000Rho-285.26Eff Leverage0.0008Vega
Amgen Stock Discussion
PRO INVESTORS - DJI PULL BACK OR DUMP MORE AND MORE NEXT FEW DAYS, SELL IN MAY FLEE AWAY BECAUSE OWE TOO MUCH 🤔
Gapping Up
$Hertz Global (HTZ.US)$ soared 17.2%, building on the previous session's momentum. On Wednesday, the stock had already jumped over 56% after Bill Ackman's Pershing Square revealed a significant investment in the company.
$Eli Lilly and Co (LLY.US)$ surged 10.8% in Thursday's premarket trading following the company's announcement that its oral GLP-1 receptor agonist, orforglipron, achieved the primary endpoi...
Breakthrough: New Cancer Drug IMDELLTRA Outperforms Standard Treatment in Survival Study
Gapping Up
$Peabody Energy (BTU.US)$ shares extended gains to 11.10% in pre-market trading after a 9.2% rise yesterday, following President Trump's executive orders aimed at reviving the U.S. coal industry. Trump plans to use the Defense Production Act to support coal mining and next-generation technologies, and instruct the DOJ to challenge regulations affecting coal jobs, aiming to enhance U.S. AI leadership by b...
On Monday, Trump suggested that he would be “very kind...
Can This New Atopic Dermatitis Drug Challenge Current Market Leaders? Phase 3 Data Reveals Key Insights
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...
No comment yet